Clinical trial
Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel…
NCT00129922 · Spanish Breast Cancer Research Group, Other · Completed
Key facts
| NCT number | NCT00129922 |
|---|---|
| Title | Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer |
| Official title | Phase III Study to Compare 6 Courses of FEC (Fluorouracil, Epirubicin and Cyclophosphamide) vs. 4 Courses of FEC Followed by 8 Weekly Paclitaxel Administrations, as Adjuvant Treatment for Node Positive Operable BC Patients |
| Lead sponsor | Spanish Breast Cancer Research Group, Other |
| Collaborators | Bristol-Myers Squibb Industry Pfizer Hoffmann-La Roche |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | paclitaxel, Fluorouracil, Epirubicin, Cyclophosphamide |
| Enrollment | 1,289 |
| Start date | Nov 1, 1999 |
| Primary completion | Dec 1, 2005 |
| Completion | Dec 1, 2007 |
| First posted | Aug 12, 2005 |
| Last update posted | Mar 6, 2023 |
| Countries | Spain |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: